

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E13/22 - Hormones 1

Deadline: 26.07.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(306) 17-OH-progesterone	[nmol/L]				3							3	3	100%							3	3	100%
Samples and groups																							
Sample A		7,53	0,82	11	3							3	3	100%	CRV	6,024	0,072	44%	3,37	8,68	3	3	100%
Other					3	0						3									3		
							1x 1/36, 2x 2/66								1x 1/36, 2x 2/66								
Sample B		19,0	2,5	13	3							3	3	100%	CRV	18,58	0,19	44%	10,4	26,8	3	3	100%
Other					3	0						3									3		
							1x 1/36, 2x 2/66								1x 1/36, 2x 2/66								
(303) Aldosterone	[nmol/L]				6							5	5	100%							0		
Samples and groups																							
Sample A		1,08	0,19	18	6							5	5	100%							0		
Other					6	0						5											
							1x 1/36, 1x 1/218, 1x 2/66, 3x 4/164																
Sample B		1,33	0,27	21	6							5	5	100%							0		
Other					6	0						5											
							1x 1/36, 1x 1/218, 1x 2/66, 3x 4/164																
(307) DHEA-S	[µmol/L]				6							6	5	83%							0		
Samples and groups																							
Sample A		15,0	1,4	9,4	6							6	5	83%							0		
Other					6	0						6											
							1x 4/1, 3x 4/12, 2x 4/60																
Sample B		7,60	0,59	7,8	6							6	6	100%							0		
Other					6	0						6											
							1x 4/1, 3x 4/12, 2x 4/60																
(302) 17-beta-estradiol	[pmol/L]				12							12	12	100%							12	12	100%
Samples and groups																							
Sample A		1220	140	11	12							12	12	100%	CRV	1269	18	30%	888	1650	12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		1340	65	4,9	5	0	CVPG	1340	6,0	22%	1040	1640									5		
(60) Roche																							
Other					7	0						7										7	
							1x 3/25, 4x 4/1, 2x 4/12								1x 3/25, 4x 4/1, 2x 4/12								
Sample B		634	48	7,6	12							12	12	100%	CRV	651,3	8,2	30%	455	847	12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		669	26	3,8	5	0	CVPG	674	3,5	22%	525	823									5		
(60) Roche																							
Other					7	0						7										7	
							1x 3/25, 4x 4/1, 2x 4/12								1x 3/25, 4x 4/1, 2x 4/12								
(200) Ferritin	[µg/L]				17							16	15	94%							0		
Samples and groups																							
Sample A		481	96	20	17							16	16	100%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		553	28	5,1	7	0	CVPG	562	7,7	24%	427	697											
(1) Abbott																							
Other					10	0						9											
							3x 4/12, 3x 4/60, 1x 6/1, 3x 6/60																

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E13/22 - Hormones 1

Deadline: 26.07.2022

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Sample B		73,7	10	14	17							16	15	94%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		74,7	2,7	3,6	7	0	CVPG	71,4	2,3	24%	54,2	88,6											
Other					10	0																	
(301) Cortisol	[nmol/L]				9																9	9	100%
Samples and groups																							
Sample A		566	45	7,9	9																9	9	100%
Other					9	0															9		
Sample B		968	83	8,6	9																9	9	100%
Other					9	0															9		
(304) Progesterone	[nmol/L]				13																13	12	92%
Samples and groups																							
Sample A		46,9	6,1	13	13																13	12	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		47,0	0,78	1,7	5	0	CVPG	46,6	0,67	20%	37,2	56								5			
Other					8	0															8		
Sample B		14,7	1,6	11	13																13	13	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		14,3	0,44	3,1	5	0	CVPG	14,4	0,28	20%	11,5	17,3								5			
Other					8	0															8		
(121) Total T3	[nmol/L]				2																2	2	100%
Samples and groups																							
Sample A		6,10	0,57	9,3	2																2	2	100%
Other					2	0															2		
Sample B		2,24	0,20	8,8	2																2	2	100%
Other					2	0															2		
(125) Free T3	[pmol/L]				15																15	14	93%
Samples and groups																							
Sample A		20,9	4,1	19	15																15	14	93%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		19,7	1,5	7,5	7	0	CVPG	19,2	0,25	15%	16,3	22,1								7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		25,3	0,41	1,6	5	0	CVPG	25,8	0,079	15%	21,9	29,7								5			
Other					3	0															3		
Sample B		8,73	1,2	14	15																15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,51	1,0	12	7	0	CVPG	8,29	0,086	15%	7,04	9,54								7			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		9,83	0,42	4,3	5	0	CVPG	10,1	0,040	15%	8,58	11,7								5			
Other					3	0															3		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E13/22 - Hormones 1

Deadline: 26.07.2022

Test	[unit]	Comparability										Traceability													
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}			
(122) Total T4	[nmol/L]				3							3	3	100%							3	2	67%		
Samples and groups																									
Sample A		118	7,4	6,3	3							3	3	100%	CRV	132,8	1,4	17%	110	156	3	2	67%		
Other					3	0						3									3				
							1x 4/1, 1x 4/12, 1x 4/60									1x 4/1, 1x 4/12, 1x 4/60									
Sample B		229	21	9,1	3							3	3	100%	CRV	249,5	2,5	17%	207	292	3	2	67%		
Other					3	0						3									3				
							1x 4/1, 1x 4/12, 1x 4/60									1x 4/1, 1x 4/12, 1x 4/60									
(124) Free T4	[pmol/L]				20							20	18	90%									0		
Samples and groups																									
Sample A		21,0	4,2	20	20							20	18	90%									0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		17,7	1,6	8,8	9	0	CVPG	17,2	0,13	13%	14,9	19,5									9				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		25,2	2,2	8,8	7	0	CVPG	25	0,13	13%	21,7	28,3									7				
Other					4	0															4				
							1x 3/25, 3x 4/12																		
Sample B		55,8	18	33	20							20	19	95%									0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		40,7	3,7	9,1	9	0	CVPG	39,1	0,61	13%	34	44,2									9				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		75,3	5,9	7,9	7	0	CVPG	74	0,46	13%	64,3	83,7									7				
Other					4	0															4				
							1x 3/25, 3x 4/12																		
(305) Testosterone	[nmol/L]				13							13	13	100%									13	12	92%
Samples and groups																									
Sample A		14,3	1,6	11	13							13	13	100%	CRV	13,82	0,14	30%	9,67	18	13	13	100%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		14,5	0,79	5,4	6	0	CVPG	14,8	0,10	22%	11,5	18,1									6				
Other					7	0															7				
							1x 3/25, 2x 4/1, 4x 4/12									1x 3/25, 2x 4/1, 4x 4/12									
Sample B		22,8	2,5	11	13							13	13	100%	CRV	21,46	0,22	30%	15	27,9	13	12	92%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		22,8	1,0	4,6	6	0	CVPG	22,9	0,16	22%	17,8	28									6				
Other					7	0															7				
							1x 3/25, 2x 4/1, 4x 4/12									1x 3/25, 2x 4/1, 4x 4/12									
(123) TSH	[mU/L]				20							20	20	100%									0		
Samples and groups																									
Sample A		24,3	3,9	16	20							20	20	100%									0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		20,9	0,45	2,2	9	0	CVPG	20,6	0,14	14%	17,7	23,5									9				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		27,8	0,69	2,5	7	0	CVPG	27,8	0,094	14%	23,9	31,7									7				
Other					4	0															4				
							1x 3/25, 3x 4/12																		
Sample B		9,94	1,5	15	20							20	20	100%									0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,61	0,18	2,1	9	0	CVPG	8,53	0,059	14%	7,33	9,73									9				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		11,5	0,22	1,9	7	0	CVPG	11,5	0,042	14%	9,89	13,2									7				
Other					4	0															4				
							1x 3/25, 3x 4/12																		